Adeno-associated Virus of a Single-polarity DNA Genome Is Capable of Transduction In Vivo
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The adeno-associated virus (AAV) is a promising vector for gene therapy. Further improvement of the virus for clinical application depends on better understanding of the molecular structure and fate of the vector genome. AAV vectors with wild-type inverted terminal repeats package either the plus- or the minus-strand DNA genomes with equal frequency. By creating a series of deletions within the, we have developed a genetic approach that can generate an AAV vector that packages its single-stranded DNA genome predominantly in a single polarity (99.4%). This novel reagent efficiently transduced muscle, brain and liver in whole animals. The transduction efficiencies were similar to those of the control mixed-polarity vectors. Our results showed that reannealing of plus- and minus-strand DNA was not required for AAV-mediated transduction in vivo, supporting the hypothesis that second-strand DNA synthesis is a primary pathway in converting the single-stranded AAV genome into double-stranded forms. The availability of the single-polarity AAV vector would aid further studies on the mechanism of AAV transduction as well as the application of AAV vector for gene replacement therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The D sequence is the packaging signal”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [232]
In the citing paper
“is important for the AAV replication”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [232]
In the citing paper
“can bind the double-stranded D sequence binding protein (ds-D-BP) [232-234]”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [232]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationZolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Self-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Self-citationMcCown, T. J., Xiao, X., Li, J., Breese, G. R., & Jude Samulski, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01488-8 · Cited by 450
Self-citationSamulski, R. J., Chang, L. S., & Shenk, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.10.3096-3101.1987 · Cited by 449
Self-citationWang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367
Self-citationDNA helicase‐mediated packaging of adeno‐associated virus type 2 genomes into preformed capsids
King, J. A., Dubielzig, R., Grimm, D., & Kleinschmidt, J. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.12.3282 · Cited by 338
Nakai, H., Storm, T. A., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9451-9463.2000 · Cited by 194
Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy
Xiao, W., Berta, S. C., Lu, M. M., Moscioni, A. D., Tazelaar, J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10222-10226.1998 · Cited by 166
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Self-citationSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
AAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Recombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
(2009) · PubMed
The Interplay between Adeno-Associated Virus and Its Helper Viruses
Meier, A. F., Fraefel, C., & Seyffert, M. (2020) · Viruses · doi:10.3390/v12060662 · Cited by 162
Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., Unali, G., Conti, A., Canarutto, D., Albano, L., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.09.001 · Cited by 133
“…50 AAV ITRs (deleted of the B-B’ and/or C-C’ reactive sequences) or mutated 30 ITR D-sequence (resulting in encapsidation of single polarity [sp] genomes into the viral capsid [Zhou et al., 2008]) did not mitigate p21 induction despite showing similar ITR CG content (Figures 2N–2P, S2Q, and S2R).”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice
Stone, D., Long, K. R., Loprieno, M. A., Feelixge, H. S. D. S., Kenkel, E. J., Liley, R. M., Rapp, S., Roychoudhury, P., Nguyen, T., Stensland, L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.014 · Cited by 101
“H whole-genome sequences.7 From these, we identified highly conserved sites within overlapping HBV reading frames with the best combinations of on- and off-target specificity scores, and further validated their conservation using an alternative dataset of 2,179 genotype C complete genome sequences.37 We then selected…”
BackgroundInfluentialAdeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements, M. E., & MacLaren, R. E. (2017) · PubMed Central · Cited by 144
A Molecular Revolution in the Treatment of Hemophilia
Butterfield, J. S. S., Hege, K. M., Herzog, R. W., & Kaczmarek, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.006 · Cited by 94
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 98
“sized from the self-primed ITR at the 3′-end [96,97], followed by strand annealing via base”
BackgroundRecombinant Adeno-Associated Viral Vector Production and Purification
Shin, J.-H., Yue, Y., & Duan, D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-343-1_15 · Cited by 54
“By deleting the d-sequence in one of the ITRs, single polarity AAV vector can also be generated containing either the plus or the minus strand only (14, 15).”
BackgroundRational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., Li, B., Cheng, B., Ma, W., Lentz, T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02581-14 · Cited by 47
“Thus, the loss of GATA-1 binding from the D-sequence-deleted AAV vectors and the acquisition of GATA-1 and GATA-2 binding in the S-sequence-substituted AAV vectors provide yet another plausible explanation for the observed difference between our previously published studies (32, 33) and those described here.”
ResultSelf-citationHordeaux, J., Dubreil, L., Deniaud, J., Iacobelli, F., Moreau, S., Ledevin, M., Guiner, C. L., Blouin, V., Duff, J. L., Mendes-Madeira, A., et al. (2015) · Gene Therapy · doi:10.1038/gt.2014.121 · Cited by 55
Sun, X., Lu, Y., Bish, L. T., Calcedo, R., Wilson, J. M., & Gao, G. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.214 · Cited by 45
“…(ds) form through either a second-strand synthesis or a self-annealing pathway, which is bypassed in the design of the sc genome format (Ferrari et al. , 1996; Fisher et al. , 1996; Hirata and Russell, 2000; McCarty et al. , 2001; Wang et al. , 2003, 2007; Zhong et al. , 2008; Zhou et al. , 2008).”
InfluentialZhong, L., Zhou, X., Li, Y., Qing, K., Xiao, X., Samulski, R. J., & Srivastava, A. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300376 · Cited by 41
Self-citationAdeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown, N. J., Song, L., Rao, K. N., & Hirsch, M. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.038 · Cited by 43
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
The Adeno-Associated Virus Genome Packaging Puzzle
Ling, C., Wang, Y., & GV, J. G. A. (2015) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000175 · Cited by 42
“Thus, even if a secondary structure at the trs cannot be formed, nicking at this site could still occur, albeit at a lower level, which might provide a reasonable explanation as to why exclusive packaging of only one strand was not seen with our D-sequence−substituted mutants [17,28-30].”
BackgroundSihn, C., Handyside, B., Liu, S., Zhang, L., Murphy, R., Yates, B., Xie, L. Y., Torres, R., Russell, C. B., O’neill, C. A., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.12.004 · Cited by 35
Fakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications
Zhou, L., & Yao, S. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00115-5 · Cited by 33
AAV- based vector improvements unrelated to capsid protein modification
Shitik, E. M., Shalik, I. K., & Yudkin, D. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1106085 · Cited by 30
“Meanwhile, such modification in one ITR combined with a complete deletion of the D-sequence in another ITR resulted in single-polarity AAV vectors being formed (49).”
BackgroundAdeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector
Srivastava, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29017.asr · Cited by 24
Zhou, Q., Tian, W., Liu, C., Lian, Z., Dong, X., & Wu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-04054-4 · Cited by 23
Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders
Limia, C. E. G., Baird, M., Schwartz, M., Saxena, S., Meyer, K., & Wein, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121979 · Cited by 31
Catalán-Tatjer, D., Tzimou, K., Nielsen, L. K., & Lavado‐García, J. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108370 · Cited by 16
Song, L., Hasegawa, T., Brown, N. J., Bower, J. J., Samulski, R. J., & Hirsch, M. L. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf013 · Cited by 14
“:3) genomic transport into preassembled capsids ( 39 ).”
Self-citationAdachi, K., & Nakai, H. (2011) · InTech eBooks · doi:10.5772/24265 · Cited by 9
“…rAAV genomes become ds DNA is not completely understood but the process involves the following two mechanisms; second-strand synthesis (Ferrari et al., 1996; Fisher et al., 1996; Zhong et al., 2008; Zhou et al., 2008) and annealing of plus and minus strands (Hauck et al., 2004; Nakai et al., 2000).”
BackgroundGalli, A., Iaia, I., Milella, M. S., Cipriani, F., Latta, V. D., Giacca, M., Zentilin, L., & Cervelli, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-020-00294-4 · Cited by 7
McAlister, V. J., & Owens, R. A. (2010) · Virology Journal · doi:10.1186/1743-422x-7-218 · Cited by 5
“[56] in our mutated ITR has only has 2, nonadjacent, bases of sequence identity with the wild-type AAV2 sequence (Fig.”
BackgroundMethodInfluentialA dual‐reference study design for understanding and improving AAV genome size analysis
Sun, Y., Lu, Z., Miller, M. D., Valcour, Y., Khimani, A. H., Bauer, J., Salomon, M., & Tong, Y. (2024) · Electrophoresis · doi:10.1002/elps.202400011 · Cited by 5
“Second, ssAAV packages either plus ( + ) or minus ( − ) strand with an equal frequency [6, 7].”
Fulmer, T. (2010) · Science-Business eXchange · doi:10.1038/scibx.2010.34 · Cited by 5
Lee, M., & Park, J. E. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108906 · Cited by 1
Tolmachov, O. E. (2010) · Spiral (Imperial College London) · Cited by 1
recombinant AAV vectors in human cell lines in vitro and in murine hepatocytes in
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., George, V., Li, B., Cheng, B., Ma, W., Lentz, T. B., et al. (2014)
Self-citationCharacterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
Metadata
- Authors
- Zhou, X., Zeng, X., Fan, Z., Li, C., McCown, T., Samulski, R. J., & Xiao, X.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Xiao, Xiao
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 494-499
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1973095007
- Cited by
- 41
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 3 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Ohio State University
- National Institutes of Health (1r21dk055966-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK55966)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR45967, R01AR045967)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, inverted terminal repeats, single-stranded DNA genome, in vivo transduction, gene therapy vectors, liver transduction, gene replacement therapy
- MeSH terms
- Dependovirus, Animals, Brain, DNA, Viral, Female, Genetic Vectors, Liver, Male, Mice, Inbred C57BL, Models, Genetic, Muscles, Transduction, Genetic, Genome, Viral, Rats, Sprague-Dawley, Green Fluorescent Proteins, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.